Econor

Selected form

There is no image.

Valnemulin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Econor

What is Econor? (Adapted Overview)

Property	Description
Active ingredient	Econazole Nitrate (INN)
Form	Topical Cream or Foam
Pharmacological class	Azole Antifungal Agent
General purpose	Treating fungal skin infections
Origin	Synthetic

1. What is Econor and How is it Classified?

Econor is a prescription-only antifungal medicine whose active ingredient is Econazole Nitrate, belonging to the azole pharmacological class of anti-infective agents. This medication is clinically recognized for targeting a broad range of common fungal and yeast organisms that cause skin infections. Econazole is available internationally under multiple brand names, as well as in generic formulations.

The azole classification places it among agents that primarily act to prevent the growth and replication of fungal organisms, allowing the body's natural defenses to resolve the infection. The active component is a synthetic organic compound produced in a laboratory to ensure consistency and high purity.

2. What is Econor Made Of and How is it Applied?

Econor is supplied as a 1% topical cream or a specialized 1% topical foam, formulated exclusively for external application to the skin. This preparation is specifically designed for localized treatment, as pharmacological studies confirm that systemic absorption from the skin surface is extremely low.

Its composition includes the active substance Econazole Nitrate and various inactive ingredients (excipients) necessary for product stability and texture. The availability of both the traditional cream and the foam allows for flexibility in application, depending on the site and type of fungal infection, such as those found in skin folds or between the toes.

3. What is the General Therapeutic Purpose of Econor?

The general therapeutic purpose of Econor is to successfully clear superficial fungal infections and restore the skin’s healthy condition. It achieves this by focusing its action directly at the site of infection. This targeted function makes Econazole a reliable external treatment used to manage various skin mycoses by disrupting the necessary structure of the fungal cells, thereby stopping the spread of the infection and promoting healing.

What side effects are possible with Econor?

Possible Side Effects and Safety Information

The safety profile for Econor, which contains Econazole Nitrate, is primarily characterized by localized reactions at the application site, reflecting the topical nature of the medicine. The adverse reactions are classified and documented by regulatory authorities, with specific groupings based on frequency and affected body systems.

Adverse Reaction Classification

Side effects are categorized based on their incidence reported in clinical trials and post-marketing surveillance:

Classification	Examples of Reactions (SOC)
Common (1-10%)	Pruritus (Itching), Skin burning sensation, Pain at the application site
Uncommon (0.1-1%)	Erythema (Redness), Rash, Swelling, Discomfort
Not Known	Hypersensitivity, Angioedema, Urticaria (Hives), Contact dermatitis, Blister, Skin exfoliation

The most commonly reported adverse effects are local reactions falling under the Skin and Subcutaneous Tissue Disorders or General Disorders and Administration Site Conditions System Organ Classes (SOC).

Serious Safety Considerations

The official safety information notes the risk of severe reactions, categorized as Serious Adverse Reactions, including Hypersensitivity and Angioedema, which are typically identified through post-marketing reports (Not Known frequency). The medication is formally contraindicated in individuals with a known hypersensitivity to any of its components.

Population and Interaction Constraints

The regulatory label includes specific safety notes for certain populations. Regarding pregnancy, animal data suggests potential fetotoxic or embryotoxic effects at high oral doses; use is generally restricted during the first trimester unless deemed essential. It is not known if the drug is excreted in human milk. A high-level safety constraint is also documented: concomitant use with oral anticoagulants, such as warfarin, may result in an enhanced anticoagulant effect, especially with application to large surface areas or under occlusion.

Overdose and Emergency Response

Overdose Scope

Category	Official Regulatory Statement
Documented overdose presentations	Overdosage of econazole nitrate in humans following topical application has not been reported to date in regulatory documentation.
Physiological systems affected	The gastrointestinal system is the primary system of concern due to the risk associated with accidental oral ingestion.
Dose-related or exposure-related factors	Accidental ingestion (swallowing) of the topical cream or foam represents the primary regulatory overdose-context factor.
Population-specific overdose notes	None are explicitly detailed in the overdose sections of the regulatory labeling.
Emergency-response statements	Contact a Poison Control center or get medical help right away if the product is accidentally swallowed.
When immediate medical help is required	Immediately following accidental oral ingestion.

Overdose Classifications (High-Level)

Category	Official Regulatory Statement
Severity classification	The regulatory profile implies a minimal risk of overdose for topical use, but a potential risk of harm following ingestion.
Regulatory basis	Information is derived from FDA Prescribing Information and aligned government health authority guidance.
Overdose-context constraints	The primary focus is constrained to the potential outcomes of accidental ingestion of the external-use product.

Resulting Overdose Structure

Official overdose statements:

Overdosage of econazole nitrate in humans has not been reported to date for the topical formulation, according to official regulatory documentation.
The highest-risk situation requiring emergency action is accidental oral ingestion of the topical cream or foam.
In the event of accidental ingestion, it is explicitly required to get medical help right away by contacting a Poison Control center or emergency services.
Official regulatory documents generally describe symptomatic and supportive treatment for managing toxicity if it occurs.

Connection to the overall overdose profile:

The regulatory overdose profile for Econor is distinct in that it focuses on the route of exposure, stating that topical overdose manifestations have not been formally documented. This dictates that the primary regulator-mandated guidance for seeking help is triggered only by the circumstance of accidental ingestion of the external-use product. Accordingly, official documents require immediate action to contact emergency medical professionals or a Poison Control center if the topical medicine is swallowed.

Therapeutic Uses of Econor

What Econor (adapted from Econazole) Treats: Main Uses and Benefits

Econor is generally used to manage the primary forms of superficial skin mycoses. It is commonly used across conditions presenting with acute or disruptive episodes of fungal growth. The medication is considered relevant for managing infections like athlete's foot (Tinea pedis), jock itch (Tinea cruris), ringworm of the body (Tinea corporis), cutaneous candidiasis (yeast infections of the skin), and Tinea Versicolor (Pityriasis versicolor).

The application is relevant in contexts marked by increased discomfort or tension, as it helps address symptom clusters that may become intense or disruptive. It is commonly used to help with symptoms related to inflammatory or irritative states, particularly itching (pruritus), burning sensation, and redness (erythema) at the infection site.

“The core therapeutic function is to address the pronounced symptoms that may lead to discomfort and interfere with the patient’s daily functioning.”

This supportive symptomatic management supports patients during episodes of heightened discomfort and helps patients cope more steadily with symptom fluctuations. Econor is also applied in clinical settings that involve acute or unstable symptom patterns, especially for infections developing in vulnerable, moisture-prone areas like interdigital spaces and skin folds. It plays a role in managing recurring or episodic manifestations of these conditions, providing supportive relief when symptoms that interfere with daily functioning are present.

Quick Fact: Relief for Inflammatory Symptoms Econor is commonly applied in scenarios where additional management of itching, burning, and redness is often appropriate due to fungal skin infection, contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Econor (Adapted from Econazole)?

Official eligibility rules for Econor (Econazole Nitrate topical) are strictly defined by government regulatory labeling, outlining specific populations that must not use the medicine and those requiring restricted or conditional use.

Contraindications and Restrictions

Eligibility Status	Population Group	Regulatory Rule Basis
CONTRAINDICATED	Individuals with a known hypersensitivity (allergy) to econazole nitrate or any excipient in the formulation.	Absolute Exclusion
RESTRICTED USE	Pregnant women, especially during the first trimester. Use is typically only if clearly needed and under specific professional determination.	Conditional Use
CONDITIONAL USE	Nursing mothers. Caution must be exercised, as it is not known if the drug is excreted in human milk.	Precautionary Status

Age-Related Eligibility

Econor is established for use in adults for all approved indications. The topical foam formulation has established safety and efficacy for adolescents 12 years of age and older. Regulatory labeling specifies that safety and efficacy for the foam have not been established in children younger than 12 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Econor (adapted from Econazole)

Interaction scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Oral Anticoagulants (coumarin derivatives).
Specific interacting medicines	Warfarin and related coumarin derivatives such as Acenocoumarol.
Mechanistic basis of interactions	Pharmacokinetic interaction leading to the enhancement of the anticoagulant effect. This enhancement is associated with increased systemic absorption of Econazole.
Timing-based interaction rules (if applicable)	No mandatory timing separation rules are documented in the official label.
Interaction-related restrictions	Mandatory biological monitoring of blood parameters when co-administered.

Interaction classifications (high-level)

Category	Classification / Factual Statement
Interaction severity classification	Clinically significant interaction requiring monitoring and potential dosage adjustment of the co-administered drug.
Regulatory basis	Documented in both FDA Prescribing Information and EMA/national SmPCs.
Interaction-context constraints	Increased risk applies particularly when Econor is applied to large body surface areas, the genital area, or under occlusion (e.g., bandages).

Resulting interaction structure

The regulatory profile for Econor is defined by a single, critical pharmacokinetic interaction with oral anticoagulants. Official statements confirm that co-administration with Warfarin or Acenocoumarol may lead to an enhanced anticoagulant effect, a risk tied to conditions that increase the drug’s systemic absorption. This requires the monitoring of the International Normalized Ratio (INR) and/or prothrombin time. No interactions with food, alcohol, or other medicinal product categories are specifically documented in official labeling.

Mechanism of Action

Econor acts as a non-competitive antagonist, selectively targeting lanosterol 14-alpha-demethylase (CYP51), a cytochrome P450 enzyme located within the endoplasmic reticulum of fungal cells. This molecular interaction interrupts the biological pathway responsible for the conversion of lanosterol to ergosterol. The primary intracellular consequence is a substantial deficit in the production of ergosterol, a critical sterol component necessary for maintaining fungal cell membrane structure and fluidity. Simultaneously, the enzymatic block causes an accumulation of intermediary sterols, which become incorporated into the cell membrane. The altered sterol composition of the membrane increases its permeability, compromising structural integrity and leading to the leakage of essential intracellular components. This molecular cascade ultimately modulates cellular homeostasis by disrupting the membrane-dependent activities, including nutrient transport and enzyme function, resulting in the cessation of fungal cellular replication and viability.

Dosage and Administration Information

Official Administration Principles

Econor (econazole nitrate) is designated exclusively for topical (external) use on the skin. It is available as a 1% cream or a specialized 1% foam formulation. The administration route is strictly dermal and is not intended for ophthalmic or internal application.

Dosing Frequency and Course Duration

The quantity applied is officially defined as a sufficient amount to adequately cover the entire symptomatic area and the immediate surrounding skin perimeter. The required frequency is standardized based on the infection being treated: application is mandated twice daily (morning and evening) for cutaneous candidiasis, while it is applied once daily for most other tinea infections, including ringworm.

The course of use must adhere to a predefined duration. Treatment for candidiasis and most tinea infections typically requires two weeks of consistent use. Conversely, the course for Tinea pedis (athlete's foot) is extended to one month (four weeks). It is specified that the full duration of treatment must be completed, even if clinical improvement is observed early.

Procedural and Age Constraints

The foam formulation requires the canister to be shaken briefly immediately prior to dispensing. Due to the flammability of the foam’s propellant, users must avoid heat, flame, and smoking during and immediately following the application process. Furthermore, the foam formulation is officially restricted to use in patients 12 years of age and older.

Recent Clinical Evidence

Econor (adapted from Econazole): Recent Clinical Evidence

Clinical evidence regarding Econazole (the compound adapted in Econor) is centered on its use as an imidazole antifungal agent. Studies have explored its efficacy and safety profile in the treatment of various superficial fungal infections, primarily dermatophytosis, candidiasis, and pityriasis versicolor.

Efficacy Across Fungal Types

Research has investigated the clinical and mycological cure rates associated with topical Econazole preparations. For tinea corporis (ringworm) and tinea cruris (jock itch), several trials observed high cure rates, generally ranging from 70% to 90% after four to six weeks of application. For cutaneous candidiasis, studies also reported positive outcomes, often comparable to other standard-of-care topical antifungals.

Infection Type	Primary Fungal Cause	General Clinical Cure Rates Studied
Dermatophytosis	Tinea species	70%–90%
Cutaneous Candidiasis	Candida species	Rates comparable to other standard topicals

Safety and Tolerability Profile

Studies evaluating the safety of topical Econazole formulations have generally indicated that the compound is well tolerated among study participants. The most commonly reported adverse events in clinical trials involved local application site reactions. These typically included mild and transient effects such as burning, stinging, itching, or erythema (redness) at the site of application. Serious adverse events or systemic toxicity were rarely observed when used as a topical preparation. Comparative research suggests the tolerability profile is similar to other agents within the topical antifungal class.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Econor (adapted from Econazole) (FAQ)

Q: What's the difference between Econor and a general antibiotic cream?

Econor is classified as an azole antifungal agent, meaning its function is to target and disrupt fungal and yeast organisms that cause skin infections. Official product information states that the active ingredient in Econor is not intended to treat infections that are caused by bacteria or viruses.

Q: Does Econor treat bacterial infections too?

Econor is primarily an antifungal agent. According to authoritative descriptions, the active ingredient's mechanism of action is specifically directed against fungal and yeast cells. Therefore, it is stated that it will not treat infections caused by bacteria or viruses.

Q: Is Econor available over-the-counter or only by prescription?

The core regulatory content provided specifies that Econor (Econazole Nitrate) is classified as a prescription-only antifungal medicine. This means it requires a healthcare professional's authorization for its use.

Q: Can Econor be used for ringworm (tinea corporis)?

Yes, the official indications for Econor include the topical treatment of tinea corporis, which is the medical term for ringworm, when caused by specific susceptible fungal species. Official administration principles provide a specific course duration for this condition.

Q: How quickly should I expect to see an improvement with Econor?

Clinical documents indicate that most patients experience early relief of symptoms after beginning treatment with Econor. Official administration principles emphasize the necessity of completing the full duration of treatment, regardless of when clinical improvement is observed.

Q: Can Econor cause a rash or irritation that looks like a worsening of the problem?

Regulatory documents classify local reactions such as redness (erythema), rash, burning, stinging, and discomfort as possible side effects. These effects occur only at the application site and may be reported by patients.

Q: Is it normal to feel a burning or stinging sensation when applying Econor?

Official documents list skin burning sensation and pain or stinging at the application site as common side effects of the topical application. This means these localized reactions are reported in 1% to 10% of patients using the medication.

Q: Can Econor interact with everyday vitamins or supplements?

Official regulatory labeling for Econor documents a critical interaction only with oral anticoagulants. The labeling does not specifically document interactions with vitamins, nutritional supplements, or other non-prescription products.

Q: Does alcohol interact with the way Econor works?

Official regulatory labeling for Econor documents a single, critical interaction with oral anticoagulants. According to these official sources, interactions with alcohol are not specifically documented.

Q: Do I need to avoid sunlight when using Econor?

Non-clinical regulatory studies examining the use of Econor foam did not indicate phototoxicity or photosensitivity. Phototoxicity is an adverse reaction that can occur when light interacts with the medication in the skin.

Q: How does Econor compare to other 'azole' antifungal creams in general terms?

Econor's active ingredient, econazole, belongs to the azole pharmacological class of antifungal agents. This classification places it among other topical antifungals, which often share a similar mechanism of action against fungal cells. Comparative research suggests its tolerability profile is generally similar to other agents within this class.

Q: What is the consistency of Econor cream or solution?

Regulatory documents describe the cream formulation as a white to off-white soft cream. The medication is also available as a specialized topical foam formulation, which is propellant-driven for specific application areas.

Q: Does Econor work on scalp fungus or dandruff?

The official indications approved by regulatory authorities for Econor are limited to the topical treatment of tinea infections and cutaneous candidiasis of the skin. The specific treatment of scalp fungus or dandruff is not included in the approved labeling for this product.

Q: Can Econor be used on sensitive areas of the body?

Econor is intended for topical use on the skin. However, regulatory documents specifically note that application to sensitive areas, such as the genital area, may increase the potential for the systemic absorption of the drug.

Q: Does Econor affect birth control pills?

Official regulatory documents for Econor do not specifically document an interaction between the active ingredient and oral contraceptive medications. The single, critical pharmacokinetic interaction documented is with oral anticoagulant medicines.

Q: What are the ingredients listed in Econor besides the active substance?

The cream formulation contains the active substance Econazole Nitrate and several inactive ingredients, also known as excipients, necessary for the product's stability and texture. Examples of these inactive ingredients listed in regulatory documents include benzoic acid, mineral oil, and purified water.

Q: Is Econor similar to Clotrimazole or Miconazole?

The active ingredient in Econor, econazole, is classified by regulators as an azole antifungal agent. This classification means it belongs to the same general pharmacological drug class as other medicines like clotrimazole and miconazole.

Q: Can Econor lose its effectiveness over time if used for repeated issues?

Clinical trial data analyzed by regulatory bodies did not indicate an increase in the Minimum Inhibitory Concentrations (MICs) of fungal samples collected after treatment, compared to baseline samples. This evidence suggests that no change in resistance was noted during the clinical study period.

Q: Why is Econor sometimes prescribed with a different ingredient, like a mild corticosteroid?

Econor is the antifungal component of the medication. Official information explains that a corticosteroid is a separate ingredient sometimes included in combination products to address associated symptoms like inflammation, redness, swelling, or itching of the skin.

Q: What is the role of Econor in treating yeast infections?

Econor is indicated for the topical treatment of cutaneous candidiasis, which is a common type of yeast infection of the skin caused by Candida species. Official administration principles provide a specific course duration and frequency for this condition.

Q: Is it true that Econor is only for external skin use?

Yes, official administration principles state that Econor is designated exclusively for external, topical use on the skin. It is not intended for ophthalmic (eye) or internal application.

Q: Does the form of the medication matter (cream, powder, spray)?

The medication is available as both a cream and a specialized foam formulation. Regulatory documents state that the foam formulation has established safety and efficacy for use only in the treatment of interdigital athlete's foot (tinea pedis between the toes) in adolescents and adults.

Q: Are there any specific parts of the body where Econor should not be applied?

Regulatory documents state that Econor should not be applied for ophthalmic use (in the eyes) and is not intended for internal use. Application should be strictly limited to the external skin surface.

Q: If I have a mild reaction, is that considered a serious side effect?

Official documents differentiate between Common or Uncommon Adverse Reactions, such as local itching or burning, and Serious Adverse Reactions. Serious reactions, typically identified through post-marketing reports, include Hypersensitivity and Angioedema.

Q: If Econor is applied to a large area of the skin, is there an increased risk of side effects?

Official documents note that application to large body surface areas, or using the product under occlusion (such as bandages), may increase the potential for systemic absorption of the drug. This is noted as a factor in the risk of potential drug interactions.

Q: Can Econor be used to prevent infections, or only to treat them?

The medication is officially indicated and studied for the treatment of existing superficial fungal skin infections. Its general therapeutic purpose, as stated in regulatory documents, is to successfully clear these infections and restore the skin's healthy condition.

Q: Does Econor treat nail fungus (onychomycosis)?

The approved indications for Econor, according to official labeling, are limited to the topical treatment of specific superficial fungal skin infections. The treatment of nail fungus (onychomycosis) is not listed among these approved indications.

How should Econor be stored and disposed of?

How to Store and Dispose of Econor (adapted from Econazole)

Official storage and disposal requirements differ by formulation and are based on regulatory labeling.

Storage Conditions

Formulation	Required Storage Condition
Cream 1%	Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Topical Foam 1%	Must be kept away from heat, flame, and direct sunlight. Do not store above 49 C (120 F).

Handling and Disposal

Both formulations must be stored out of the reach of children. The topical foam container is flammable and under pressure; therefore, it must not be punctured or incinerated during disposal. All unused or expired product must be discarded in accordance with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.